


CASE STUDY

Nicole Kopari, MD / Department of Surgery at the University of California San Francisco, Fresno, CA

患者の状態

入浴時、臀部に4% TBSAの高温液体による熱傷を受傷した88歳男性。事前の病歴には、心房細動、脳卒中、慢性腎疾患、高血圧、脂質異常症が含まれている。




結語

本症例では、共存疾患を持ち、創傷治療遅延リスクがある高齢者の治療困難な部位の治療が示されている。RECELLを使用した事により、治療の翌日に患者は退院できた。自家細胞からなるSpray-On Skin Cellsを使用することで、術後8日目には再上皮化、1か月目には明らかな色素再生が得られるという結果が得られた。

初回デブリードマン



術後8日



術後1か月



治療法

初回デブリードマン実施後(図A)、創部のドレッシング交換をXeroform[™] / バシトラシンを使用して行った。熱傷受傷から10日後、創部デブリードマンを行い、Spray-On Skin[™] CellsをRECELL[®]システムで作成した。細胞懸濁液を損傷を受けていない真皮の上に直接適用した。創部の被覆にはTelfaTMClear、その上からXeroform及び厚みのあるドレッシング材を使用した。

臨床的アウトカム

術後1日、患者は退院し帰宅。術後8日に創部が完全上皮化したため、クリニックで一次ドレッシング材を除去した(図B)。術後1週間が経過するまでに色素の再生が明らかとなった(図C)。Spray-On Skin Cellsを作成に必要な採皮面積は最小限で済んだ。Donor site requirements for preparation of Spray-On Skin Cells were minimal, as pictured in the lower right-hand corners of Figures B and C.



INSIDE BURN PATIENTS' SKIN CELLS ARE
REGENERATIVE FORCES AT THE READY.

GIVE THEM THE SIGNAL TO MOVE.

Visit RECELLsystem.com to learn more.

IMPORTANT SAFETY INFORMATION

INDICATIONS FOR USE: The RECELL® Autologous Cell Harvesting Device is indicated for the treatment of acute thermal burn wounds in patients 18 years of age and older. The RECELL® device is used by an appropriately licensed healthcare professional at the patient's point of care to prepare autologous RES® Regenerative Epidermal Suspension for direct application to acute partial-thickness thermal burn wounds or application in combination with meshed autografting for acute full-thickness thermal burn wounds.

CONTRAINDICATIONS: RECELL® is contraindicated for the treatment of wounds clinically diagnosed as infected or with necrotic tissue present in the wound bed. RECELL® is contraindicated for the treatment of patients with a known hypersensitivity to trypsin or compound sodium lactate solution (Hartmann's Solution). The skin sample collection procedure specified for use of RECELL® should not be used with patients having a known hypersensitivity to anesthetics, adrenaline/epinephrine, povidone-iodine, or chlorhexidine solutions.

WARNINGS: Autologous use only. Wound beds treated with a cytotoxic agent (e.g., silver sulfadiazine) should be rinsed prior to application of the cell suspension. RECELL® is provided sterile and is intended for single use. Do not use RECELL® or device components if packaging is damaged, there are signs of tampering or date of use is beyond the stated expiration date. Choose a skin sample

donor site that shows no evidence of surrounding cellulitis or infection. The skin sample should be processed immediately after harvesting. If a skin sample is harvested and processed according to these instructions, it should require between 15 and 30 minutes of contact with the Enzyme. Contact in excess of 60 minutes is not recommended. RECELL® Enzyme is animal derived and freedom from infectious agents cannot be guaranteed.

PRECAUTIONS: RECELL® is not intended to be used alone (i.e., without meshed autograft) for treatment of full-thickness burn wounds. The safety and effectiveness of RECELL® used alone (i.e., without meshed autograft) have not been established for treatment of partial-thickness burn wounds: on the hands and articulated joints, >320 cm², in patients with wounds totaling >20% Total Body Surface Area (TBSA). The safety and effectiveness of RECELL® plus autografting have not been established for treatment of full-thickness burn wounds: on the hands and articulated joints, in patients with wounds totaling >50% Total Body Surface Area (TBSA).

SPECIAL PATIENT POPULATIONS: The safety and effectiveness of RECELL® have not been established for treatment of acute thermal partial-thickness or full-thickness burn wounds in pediatric patients younger than 18 years of age.

For complete Important Safety Information, refer to Instructions for Use at RECELLSystem.com.